September 30, 2016
CORRECTING and REPLACING – Novocure to Report Third Quarter 2016 Financial Results
ST. HELIER, Jersey, Sept. 30, 2016 (GLOBE NEWSWIRE) — In a press release issued under the same headline earlier today by Novocure, Ltd. (Nasdaq:NVCR), please note that the first paragraph should say “the three and nine months ended Sept. 30, 2016” rather than “the three and six months ended Sept. Read More
learn more
September 30, 2016
Novocure to Report Third Quarter 2016 Financial Results
ST. HELIER, Jersey, Sept. 30, 2016 (GLOBE NEWSWIRE) — Novocure (NASDAQ:NVCR) announced today that it will report financial results for the third quarter 2016 on Wednesday, Nov. 2, 2016, before the open of U.S.-based financial markets. Novocure management will host a conference call and webcast to discuss its financial results… Read More
learn more
September 19, 2016
CNS Oncology Publishes Tumor Treating Fields Treatment Planning and Patient Follow-up Guidelines in Glioblastoma
Guidelines provide a framework for using the NovoTAL System to optimize Tumor Treating Fields intensity in Optune patients Tumor Treating Fields extend overall survival when combined with maintenance temozolomide in newly diagnosed glioblastoma patients September 19, 2016 07:30 AM Eastern Daylight Time ST. HELIER,… Read More
learn more
September 15, 2016
Novocure’s Executive Chairman William Doyle to Present on Tumor Treating Fields at New York Academy of Sciences’ Symposium on Bioelectronic Medicine
The NYAS’ 13th Key Symposium 2016: Bioelectronic Medicine – Technology Targeting Molecular Mechanisms brings together thought leaders to advance this growing frontier of patient care September 15, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that Executive Chairman William Doyle… Read More
learn more
September 14, 2016
Two Institutions Publish Independent Data on Novocure’s Tumor Treating Fields
Publications represent growing interest from scientific community in Novocure’s broadly applicable mechanism of action September 14, 2016 08:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that two independent institutions published scientific research on Tumor Treating Fields (TTFields), representing increasing external… Read More
learn more
September 12, 2016
Long-term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Superior Progression Free and Overall Survival Seen in the Trial’s Interim Analysis
Data demonstrate superior two, three and four year survival of patients treated with Optune™ together with temozolomide Martin Romero Sanchez of Houston, Texas, is an Optune patient. Download Full Size Small… Read More
learn more
September 1, 2016
International Journal of Cancer Publishes Data Showing Tumor Treating Fields in Combination with Paclitaxel is Therapeutically Effective against Ovarian Cancer Cells in Vitro and in Vivo
Novocure has completed enrollment of a phase 2 pilot trial in ovarian cancer and will present data on Dec. 12, 2016 September 01, 2016 07:00 AM Eastern Daylight Time ST. HELIER, JERSEY–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that data showing Tumor Treating Fields (TTFields) in… Read More
learn more
